# A Study of MK0364 in Obese Patients (0364-014)

> **NCT00131391** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2400 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Comparator: taranabant
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00131391
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2008-02
- **Final completion:** 2008-12
- **Target enrollment:** 2400 (ACTUAL)
- **Why stopped:** The overall profile does not support development for obesity
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131391, "A Study of MK0364 in Obese Patients (0364-014)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00131391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*